BIOE Bio Essence Corp
Pharmaceutical Preparations · OTC · SEC CIK 1723059 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY435.2%
TTM net income YoY943.9%
TTM EPS YoY—
Revenue 3-yr CAGR46.9%
Net income 3-yr CAGR—
Margins
Gross margin68.4%
Operating margin45.1%
Net margin44.7%
FCF margin—
EBITDA margin54.3%
Returns
ROE—
ROA64.7%
ROIC (approx.)—
Asset turnover1.45x
Leverage & solvency
Liabilities / assets42.7%
Debt / equity0.02x
Current ratio0.17x
Interest coverage-286.41x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio39.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.90M | $323,940 | $551,506 | $621,590 | $887,984 |
| Cost of revenue | $469,153 | $106,863 | $274,060 | $293,264 | $589,660 |
| Gross profit | $1.43M | $217,077 | $277,446 | $328,326 | $298,324 |
| SG&A expense | $497,809 | $676,515 | $345,590 | $763,146 | $1.08M |
| Operating income | $900,011 | -$459,438 | -$345,590 | -$511,138 | -$857,527 |
| Interest expense | $2,186 | $2,153 | $2,197 | $14,131 | $38,558 |
| Pretax income | $896,997 | -$1.56M | -$403,004 | -$525,384 | -$644,264 |
| Income tax | $800 | $800 | $1,600 | $2,500 | $3,300 |
| Net income | $896,197 | -$1.31M | -$971,879 | -$809,679 | -$647,564 |
| EBITDA | $900,246 | -$458,527 | -$340,797 | -$496,625 | -$821,725 |
| EPS (basic) | — | -0.03 | -0.03 | -0.02 | -0.02 |
| EPS (diluted) | — | -0.03 | -0.03 | -0.02 | -0.02 |
| Weighted avg. shares (diluted) | 38.01M | 38.01M | 35.95M | 33.01M | 33.01M |
| Banking | |||||
| Deposits | — | — | — | $41,841 | $41,841 |
| Balance sheet | |||||
| Cash & equivalents | — | $1,371 | $114 | $6,262 | $303 |
| Receivables | $23,454 | $5,124 | $35,093 | $5,599 | $16,820 |
| Inventory | — | — | $143,259 | $181,163 | $212,969 |
| Current assets | $422,377 | $280,692 | $300,000 | $203,831 | $261,962 |
| PP&E, net | — | — | $3,688 | $246,379 | $180,909 |
| Intangibles | $97 | $332 | $567 | $802 | $1,037 |
| Total assets | $422,474 | $281,024 | $2.76M | $1.55M | $1.70M |
| Current liabilities | $2.44M | $2.80M | $2.45M | $3.56M | $2.76M |
| Long-term debt | $57,482 | $56,481 | — | — | — |
| Total debt | $57,482 | $56,481 | — | — | — |
| Total liabilities | $2.50M | $3.25M | $4.42M | $4.79M | $4.13M |
| Shareholders' equity | -$2.07M | -$2.97M | -$1.66M | -$3.24M | -$2.43M |
| Net debt | — | $55,110 | — | — | — |
| Shares outstanding | 38.01M | 38.01M | 38.01M | 33.01M | 33.01M |
| Cash flow statement | |||||
| Operating cash flow | $1.57M | $623,865 | -$1.03M | -$703,241 | -$1.29M |
| Capital expenditure | — | — | $3,614 | $3,742 | $119,496 |
| Free cash flow | — | — | -$1.03M | -$706,983 | -$1.41M |
| Investing cash flow | — | -$114 | -$91,484 | -$59,120 | -$116,796 |
| Financing cash flow | -$1.57M | -$622,494 | $1.11M | $768,320 | $1.41M |
| Depreciation & amortization | $235 | $911 | $4,793 | $14,513 | $35,802 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.